What is an Accelerated Share Repurchase (ASR) and why is Merck undertaking one?

An Accelerated Share Repurchase (ASR) is an agreement where a company buys back its own shares from an investment bank (in this case, Goldman Sachs). Merck is undertaking this ASR as a way to return capital to its shareholders and to opportunistically repurchase its stock, signaling management's confidence in the company's valuation and future prospects. It's part of their ongoing share repurchase program.

How many shares will Merck ultimately repurchase?

The exact number of shares Merck will ultimately repurchase is not fixed at the time of the announcement. An initial delivery of approximately 99.5 million shares was made. However, the final number of shares will be based on the average daily volume-weighted average price of Merck's common stock during the term of the ASR. This means the final count could be more or fewer shares than initially delivered, depending on the stock price performance during the ASR period.

When will this share repurchase program be completed?

The final settlement of the ASR agreement is expected to occur in the fourth quarter of 2013. However, the agreement allows for the possibility of earlier settlement at Goldman Sachs' option or later settlement under certain circumstances.

Could this ASR affect Merck's financial statements or future share count significantly?

Yes, the ASR will reduce the number of outstanding shares, which can positively impact earnings per share (EPS) calculations if earnings remain constant or grow. The initial transaction involves a significant cash outflow of $5 billion. The final impact on the share count will depend on the stock's trading price during the ASR period. Merck also has the option to settle any adjustment payments in cash or stock.

MRK 8-K: Material Agreements

Summary

Merck & Co., Inc. (MRK) announced on May 20, 2013, a significant accelerated share repurchase (ASR) agreement with Goldman Sachs for approximately $5 billion. This transaction underscores Merck's commitment to returning capital to shareholders and managing its capital structure effectively. The ASR involves an initial delivery of roughly 99.5 million shares to Merck, funded by Merck's $5 billion payment, with the final share count to be determined by market prices over the ASR term, expected to conclude in the fourth quarter of 2013. This move is a strong signal of management's confidence in the company's future and its stock valuation. Investors should view this ASR as a positive development, indicating Merck's proactive approach to shareholder value enhancement through opportunistic capital allocation, rather than a sign of distress. The flexibility in final settlement, including potential cash or stock adjustments, provides Merck with options depending on market conditions and corporate needs.

Key Highlights

1Merck entered into a $5 billion Accelerated Share Repurchase (ASR) agreement with Goldman Sachs.
2The ASR aims to repurchase a substantial amount of Merck's common stock.
3An initial delivery of approximately 99.5 million shares was made to Merck on May 21, 2013.
4Merck made a $5 billion payment to Goldman Sachs concurrent with the initial share delivery.
5The final number of shares repurchased will be determined by the volume-weighted average price of Merck's stock during the ASR term.
6Final settlement is expected in the fourth quarter of 2013, with potential for earlier or later completion.
7The ASR was executed under Merck's previously authorized share repurchase program.

Merck & Co., Inc. 8-K Report, Material Agreement (May 22, 2013)

Summary

Key Highlights

Frequently Asked Questions